Accelerating growth strategy

The new funding will be used to accelerate Vidiia’s growth strategy.

David Rimer, CEO and Founder of Vidiia: “With the funds we can implement our growth strategy, which aims to commercialise existing assays ready for market, develop new assays with universities and enhance our AI powered testing platform. Vidiia’s Assay Accelerator service, pulls tests off university benches and gets them to market, which we have now proven several times.”

Strong testing platform

Vidiia has a strong testing platform, which is explained by Dr Nick Hutchings, one of the investors in this round: "We need more assays, quicker! Assays are reproducible tools that allow us to understand medicine and biology at a molecular level. I am excited to join Vidiia and help scientists to develop and commercialise new assays on the world class Vidiia platform.”

Sven Kempers, director at 819 Capital Partners, expresses trust in Vidiia’s platform and team: “Vidiia’s testing platform provides many testing options for rapid diagnoses. We are confident that the team will successfully execute the growth strategy.”

Academic validation

Vidiia has strong support from academic institutions, such as Brunel University London and University of Surrey.

Dr Averil Horton, Head of Business Development and Innovation, Brunel University London, explains: “The Vidiia Assay Development Programme has enabled Brunel to place innovative bio-science IP within a structured framework to commercialisation. Their methodology and AI powered testing platform mean they have the end-to-end knowledge and tools for success. Getting IP from bench to market at speed is a big challenge for universities and Vidiia make this possible.”

Professor Lisa Collins, Pro-Vice-Chancellor, Research and Innovation at the University of Surrey, said: “It is fantastic to see the groundbreaking research of our scientists being brought to market with the help of Vidiia. It is important that the scientific community and industry partners continue to work together to develop innovative testing products to identify infectious diseases. The COVID-19 pandemic caught us all off guard and it is crucial that we improve our preparedness to protect the future health of our population.”

Professor Roberto La Ragione, Professor of Veterinary Microbiology and Pathology, School of Veterinary Medicine, and Head of the School of Biosciences at the University of Surrey, said: “Infectious diseases remain a global threat to human and animal health, and our economies. Funding is necessary to enable Vidiia and our scientists to continue our work in developing highly accurate and rapid tests to prevent the next pandemic. The earlier a person or animal is diagnosed, the quicker the disease can be contained.” 

Hands-on experience

David Rimer, concludes that investment brings more than just the funding: “We are delighted to be working with 819 and Dr Nick Hutchings. Both parties bring the crucial hands-on experience and connections that Vidiia were looking for. The continued support from our university partners also provides a significant boost beyond financial investment. It is crucial for the scientific community and society that we continue to help UK universities take tests from bench to market and make impact.”

819 Capital Partners invested in Vidiia Ltd. from 819 Evergreen Fund.

More information about Vidiia Ltd. can be found here: https://vidiia.com/